Nephrology and Transplantation.
Endocrinology, Department of Internal Medicine, Erasmus Medical Center, Rotterdam, the Netherlands.
Cytotherapy. 2018 Jul;20(7):919-929. doi: 10.1016/j.jcyt.2018.05.005. Epub 2018 Jun 20.
Mesenchymal stromal cells (MSCs) are studied for their immunotherapeutic potential. Prior to therapeutic use, MSCs are culture expanded to obtain the required cell numbers and, to improve their efficacy, MSCs may be primed in vitro. Culture expansion and priming induce phenotypical and functional changes in MSCs and thus standardisation and quality control measurements come in need. We investigated the impact of priming and culturing on MSC DNA methylation and examined the use of epigenetic profiling as a quality control tool.
Human umbilical cord-derived MSCs (ucMSCs) were cultured for 3 days with interferon (IFN)γ, transforming growth factor (TGF)β or a multi-factor combination (MC; IFNγ, TGFβ and retinoic acid). In addition, ucMSCs were culture expanded for 14 days. Phenotypical changes and T-cell proliferation inhibition capacity were examined. Genome-wide DNA methylation was measured with Infinium MethylationEPIC Beadchip.
Upon priming, ucMSCs exhibited a different immunophenotype and ucMSC(IFNγ) and ucMSC(MC) had an increased capacity to inhibit T-cell proliferation. DNA methylation patterns were minimally affected by priming, with only one significantly differentially methylated site (DMS) in IFNγ- and MC-primed ucMSCs associated with autophagy activity. In contrast, 14 days after culture expansion, ucMSCs displayed minor phenotypical and functional changes but showed >4000 significantly DMSs, mostly concerning genes involved in membrane composition, cell adhesion and transmembrane signalling.
These data show that DNA methylation of MSCs is only marginally affected by priming, whereas culture expansion and subsequent increased cellular interactions have a large impact on methylation. On account of this study, we suggest that DNA methylation analysis is a useful quality control tool for culture expanded therapeutic MSCs.
间充质基质细胞(MSCs)因其免疫治疗潜力而受到研究。在治疗用途之前,需要对 MSCs 进行培养扩增以获得所需的细胞数量,并且为了提高其疗效,可以对 MSCs 进行体外预刺激。培养扩增和预刺激会引起 MSCs 的表型和功能变化,因此需要进行标准化和质量控制测量。我们研究了预刺激和培养对 MSC DNA 甲基化的影响,并探讨了使用表观遗传谱分析作为质量控制工具的可能性。
用人脐带衍生的 MSCs(ucMSCs)用干扰素(IFN)γ、转化生长因子(TGF)β或多因子组合(IFNγ、TGFβ和维甲酸)培养 3 天。此外,还对 ucMSCs 进行了 14 天的培养扩增。检测表型变化和 T 细胞增殖抑制能力。使用 Infinium MethylationEPIC Beadchip 进行全基因组 DNA 甲基化测量。
在预刺激时,ucMSCs 表现出不同的免疫表型,ucMSC(IFNγ)和 ucMSC(MC)抑制 T 细胞增殖的能力增强。预刺激对 DNA 甲基化模式的影响很小,只有一个在 IFNγ 和 MC 预刺激的 ucMSCs 中与自噬活性相关的显著差异甲基化位点(DMS)。相比之下,培养扩增 14 天后,ucMSCs 表型和功能变化较小,但出现了>4000 个显著的 DMS,主要涉及膜成分、细胞粘附和跨膜信号转导相关的基因。
这些数据表明,MSCs 的 DNA 甲基化仅受预刺激的轻微影响,而培养扩增和随后细胞间相互作用对甲基化有很大影响。基于这项研究,我们建议 DNA 甲基化分析是一种有用的培养扩增治疗性 MSCs 的质量控制工具。